As of July 13, 2022, approximately 53.7 million people in the United Kingdom had received the first dose of the COVID-19 vaccination. The UK was the first country in the world to approve the use of the Pfizer/BioNTech vaccine, and began inoculations on December 8, 2020. Nearly all the vaccines currently being used in the UK require two doses for full efficacy to occur, and according to the latest data around 50.3 million people had received their second dose of the immunization. Furthermore, 40.1 million booster vaccinations had been administered.

The total number of cases in the UK can be found here. For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

The number of COVID-19 vaccination doses administered in the United Kingdom rose to 151248820 as of Oct 27 2023. This dataset includes a chart with historical data for the United Kingdom Coronavirus Vaccination Total.

As of April 13, 2021, the United Kingdom government had ordered 457 million doses of various COVID-19 vaccines. The UK government has ordered 100 million doses each of the AstraZeneca and Valneva vaccines. On December 2, 2020, the UK became the first country in the world to approve the Pfizer/BioNTech vaccine, and the first inoculations took place six days later on December 8. The Pfizer/BioNTech immunization requires two injections several weeks apart for full immunity to occur, which means the initial order of 40 million doses is enough for 20 million individuals to be vaccinated. The total number of cases in the UK can be found here. For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

Age-standardised mortality rates for deaths involving coronavirus (COVID-19), non-COVID-19 deaths and all deaths by vaccination status, broken down by age group.

The NHSBSA makes payments for Covid-19 vaccinations to Primary Care Network (PCN) providers in England. May I request the following data, separated per administration month, starting from 1st April 2024 to 31st August 2024, in excel format: Column 1 Year/month Column 2 ODS Code for PCN Column 3 ICS Code for the PCN Column 4 ICS Name for the PCN Column 5 Number of vaccines administered by the PCN Column 6 Total Payment made for administration of these Covid-19 vaccinations Column 7 Total of ALL other miscellaneous payments relating to Covid-19 vaccinations made to PCN. If the August data is not available at the time of processing this request then please can you send me the data for April-July Response I can confirm that the NHSBSA holds the information you have requested and a copy of the information and notes explaining it is attached. Please read the below notes to ensure correct understanding of the data. Columns 2 and 3, Integrated Care Service (ICS) code and name I am writing to advise you that following a search of our paper and electronic records, I have established that the information you requested is not currently held by the NHS Business Services Authority. We do not hold the ICS for PCNs in our database. The ODS portal can be used to identify links to ICS or 'Integrated Care Board (ICB). This can be found at: https://odsportal.digital.nhs.uk/ Columns 7 Total of ALL other miscellaneous payments relating to Covid-19 vaccinations made to PCN Please note that NHSBSA do not hold information on miscellaneous payments, but column 7 shows information on 'adjustments' which could be either a payment or a deduction, following post-payment verification. The NHSBSA calculates payments for covid vaccinations to Pharmacies and Primary Care Network (PCN) providers in England. Covid vaccination data is keyed in via Point of Care (POC) Systems and they transferred to the NHSBSA Manage Your Service (MYS) application. Each month, vaccine providers submit claims to request payment based on the data that has been transferred into MYS. To be paid in a timely fashion such claims must be submitted during a specified declaration submission period. Should claims be submitted outside the submission period they will be processed in the following period. This means that in some cases there is a difference between the number of vaccines that have been 'claimed' and the number that have been 'paid'. Both the number of 'claimed' and 'paid' vaccinations have been reported in this request. When considering the nature of the vaccine data there are several ways it can be reported over time: Administration Month This is the month in which the vaccine was administered to the patient. Payment Month This is the month in which the payment was made dispenser of the vaccine. Note that all payments for Pharmacies are paid one month later than those for PCN providers. Keying Month This is the month in which the vaccine record first appeared on the MYS system. Submission/Claim Month This is the month in which the claim for payment for a vaccination occurred. For example, suppose that a PCN patient is given a covid vaccination dose 1 in January (Administration Month) and then the paper record of this is misplaced for a while. The record is found and keyed into a POC system during February (Keying Month). The Provider is allowed to claim for keying during February in the first 5 days of March, but they're a little late and authorise the claim on the 7th of March (Submission Month) As the claim is outside the submission window it is not paid in March, it will instead be paid during April (Payment Month). Another example could be a Pharmacy patient given a covid vaccination dose 1 in January (Administration Month), keyed in January (Keying Month), then submitted in February (Submission Month) and then payments are calculated in February, however as this is for a pharmacy the payments are held back and not paid until March (Payment Month). For the purposes of this request, we have chosen to report by Administration Month. We do not hold PCN data that we can confidently join to the Lead PCN Practice ODS Code and so data is at Lead PCN Practice level. Data included in this request is limited to vaccinations carried out by PCNs only. Data included in this request is also limited to vaccinations administered between April 2024 and August 2024. The latest data used is a snapshot of the MYS system data that was taken on 6th September 2024. This is the snapshot of data taken after the August 2024 submission period that was used to calculate payments. This payment data does not include any adjustments made by NHSBSA Provider Assurance as part of post payment verification exercise. These adjustments are made at account level and may relate to several months of activity. Payment data includes payments made and those scheduled for payment in the future. Payments comprise an Item of Service fee and potentially a Supplementary fee. Payments do not relate to the value of the drugs dispensed. The total used for the payment calculation may not match the totals shown in 'live' POC systems or MYS that continue to receive updates after the snapshot used to calculate payments was taken. Vaccination records are limited to those which have been associated with a declaration submission. This may include late submission declarations received after the deadline for declarations such records are not processed until the next month. Please note that some vaccinations attract a supplementary fee, so it is not possible to determine the number of vaccinations by dividing the total paid by the basic Item of Service (IoS) fee. It is possible for new records from old administration months to be entered in the future, thus the totals here for each administration month could change when more data is processed.

Estimates of the risk of hospital admission for coronavirus (COVID-19) and death involving COVID-19 by vaccination status, overall and by age group, using anonymised linked data from Census 2021. Experimental Statistics.

Outcome definitions

For this analysis, we define a death as involving COVID-19 if either of the ICD-10 codes U07.1 (COVID-19, virus identified) or U07.2 (COVID-19, virus not identified) is mentioned on the death certificate. Information on cause of death coding is available in the User Guide to Mortality Statistics. We use date of occurrance rather than date of registration to give the date of the death.

We define COVID-109 hospitalisation as an inpatient episode in Hospital Episode Statistics where the primary diagnosis was COVID-19, identified by the ICD-19 codes (COVID-19, virus identified) or U07.2 (COVID-19, virus not identified). Where an individual had experienced more than one COVID-19 hospitalisation, the earliest that occurred within the study period was used. We define the date of COVID-19 hospitalisation as the start of the hospital episode.

ICD-10 code

U07.1 :

COVID-19, virus identified

U07.2:

COVID-19, virus not identified

Vaccination status is defined by the dose and the time since the last dose received

Unvaccinated:

no vaccination to less than 21 days post first dose

First dose 21 days to 3 months:

more than or equal to 21 days post second dose to earliest of less than 91 days post first dose or less than 21 days post second dose

First dose 3+ months:

more than or equal to 91 days post first dose to less than 21 days post second dose

Second dose 21 days to 3 months:

more than or equal to 21 days post second dose to earliest of less than 91 days post second dose or less than 21 days post third dose

Second dose 3-6 months:

more than or equal to 91 days post second dose to earliest of less than 182 days post second dose or less than 21 days post third dose

Second dose 6+ months:

more than or equal to 182 days post second dose to less than 21 days post third dose

Third dose 21 days to 3 months:

more than or equal to 21 days post third dose to less than 91 days post third dose

Third dose 3+ months:

more than or equal to 91 days post third dose

Model adjustments

Three sets of model adjustments were used

Age adjusted:

age (as a natural spline)

Age, socio-demographics adjusted:

age (as a natural spline), plus socio-demographic characteristics (sex, region, ethnicity, religion, IMD decile, NSSEC category, highest qualification, English language proficiency, key worker status)

Fully adjusted:

age (as a natural spline), plus socio-demographic characteristics (sex, region, ethnicity, religion, IMD decile, NSSEC category, highest qualification, English language proficiency, key worker status), plus health-related characteristics (disability, self-reported health, care home residency, number of QCovid comorbidities (grouped), BMI category, frailty flag and hospitalisation within the last 21 days.

Age

Age in years is defined on the Census day 2021 (21 March 2021). Age is included in the model as a natural spline with boundary knots at the 10th and 90th centiles and internal knots at the 25th, 50th and 75th centiles. The positions of the knots are calculated separately for the overall model and for each age group for the stratified model.

This statistical report, co-authored with the UK Health Security Agency (UKSHA), reports childhood vaccination coverage statistics for England in 2023-24. Data relates to the routine vaccinations offered to all children up to the age of 5 years, derived from the Cover of Vaccination Evaluated Rapidly (COVER). Additional information on children aged 2 and 3 vaccinated against seasonal flu are collected from GPs through UKHSA's ImmForm system.

As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.

The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

This dataset is no longer updated, find vaccination data here From 24 March 2022, Public Health Scotland (PHS) began reporting the number of people who have received a fourth dose of Covid-19 vaccination. Vaccine uptake statistics among care home residents and those who are severely immunosuppressed will be reported initially. PHS will include further updates as the Spring/Summer vaccination programme rolls out. In addition, as part of our continuous review of reporting, PHS made some changes to vaccine uptake statistics. From 24 March 2022, the deceased and those who no longer live in Scotland are no longer be included in vaccine uptake statistics. Historic trend data have been updated to take into account this new methodology for all apart from the Daily Trends by JCVI Priority Group table (more details about the data in this table are below). Scotland level data for all vaccinations administered (i.e. including those who have since died or moved from Scotland) are still available in the Daily Trend of All Vaccinations Delivered in Scotland table. Also from 24 March 2022, Dose 3/Booster doses are termed "Dose 3". To allow new data to be fully processed and available at 14:00, the Daily COVID-19 in Scotland and COVID-19 Vaccination in Scotland datasets will be temporarily unavailable from 12:45 to 14:00. During this window, the datasets will not be visible and any queries made to these datasets will return a 404 - Not found error. At all other times the datasets will be available in full as usual. PHS reviewed the JCVI priority group uptake figures from 18 November 2021, specifically how we derive the numerator and the denominator. The rational for the change is to ensure we report on most up to date living population for each group. For this, the list of individuals in each cohort has been refreshed to be more current. We have also removed individuals who have since died to reflect the current living population. From the 24 March 2022 those who are no longer living in Scotland have also been removed from the numerator and denominator for JCVI priority group uptake figures. This means all the JCVI cohorts and populations have changed for both numerator and denominators on these two dates and care should be taken when interpreting trends. On 08 December 2020, a Coronavirus (COVID-19) vaccine developed by Pfizer BioNTech (Comirnaty) was first used in the UK as part of national immunisation programmes. The AstraZeneca (Spikevax) vaccine was also approved for use in the national programme, and rollout of this vaccine began on 04 January 2021. Moderna (Vaxzevria) vaccine was approved for use on 8 January 2021 and rollout of this vaccine began on 07 April 2021. These vaccines have met strict standards of safety, quality and effectiveness set out by the independent Medicines and Healthcare Products Regulatory Agency (MHRA). Those giving the vaccine to others were the first to receive the vaccination. In the first phase of the programme, NHS Scotland followed the independent advice received from the Joint Committee on Vaccination and Immunisation (JCVI) and prioritised delivery of the vaccine to those with the greatest clinical need, in line with the recommended order of prioritisation. For booster vaccinations a similar approach has been adopted. Definitions used in the vaccine uptake by JCVI priority group resource can be found in the JCVI Priority Group Definitions table. Individuals can appear in more than one JCVI priority group. This dataset provides information on daily number of COVID vaccinations in Scotland. Data on the total number of vaccinations in Scotland is presented by day administered and vaccine type, by age group, by sex, by non-age cohorts and by geographies (NHS Board and Local Authority). As the population in the cohorts can change with time, these will be refined when updated data are available. Additional data sources relating to this topic area are provided in the Links section of the Metadata below. Data visualisation and additional notes are available on the Public Health Scotland - Covid 19 Scotland dashboard.

Estimates of the risk of hospital admission for coronavirus (COVID-19) and death involving COVID-19 by vaccination status, in England, using anonymised linked data from Census 2021. Vaccine effectiveness estimates are given for the whole study population and stratified by age groups. Experimental Statistics.

Children for whom the local authority is responsible who completed a course of Meningococcal group B (MenB) vaccine at any time by their first birthday as a percentage of all children whose first birthday falls within the time period.RationaleThe MenB vaccine protects against invasive meningococcal disease caused by capsule group B, which most commonly presents as septicaemia, meningitis, or a combination of both. The vaccine was introduced into the routine childhood immunisation programme in September 2015 for babies at 8 and 16 weeks of age, with a booster dose after the first birthday.Vaccination coverage is the best indicator of the level of protection a population has against vaccine-preventable communicable diseases. Coverage is closely correlated with levels of disease. Monitoring coverage helps identify possible drops in immunity before disease levels rise. The MenB vaccine is given to all children under two years old as part of the childhood vaccination programme.Previous evidence shows that highlighting vaccination programmes encourages improvements in uptake levels. This may also be relevant for NICE guidance PH21: Reducing differences in the uptake of immunisations, which aims to increase immunisation uptake among those under 19 years from groups where uptake is low.Definition of numeratorTotal number of children in LA responsible population whose first birthday falls within the time period who received two doses of MenB at any time before their first birthday.Definition of denominatorTotal number of children in LA responsible population whose first birthday falls within the time period. Coverage figures are supplied for patients registered with GPs based in that LA and for unregistered patients who were resident in that LA. The LA responsible population is therefore different from the estimated resident population figures produced by the Office of National Statistics (ONS) for each LA. For the COVER collection, the LA responsible population is usually derived from the population registers held on CHISs.CaveatsFull GP postcodes are used to aggregate data to ICB. The GP-level coverage data is collected by NHS Digital Strategic Data Collection Service (SDCS) and published by the UK Health Security Agency (UKHSA) COVER team. ICB data is experimental and should be treated with caution as it is not an official statistic.MenB primary data are available as National Statistics for the first time in 2017 to 2018. Information on childhood immunisation coverage at ages one, two, and five is collected through the UK COVER collection by UKHSA. These aggregated data are collected from CHISs, computerised systems storing clinical records that support health promotion and prevention activities for children, including immunisation. In England, COVER data are collected for Upper Tier Local Authorities (LAs) using the COVER data collection form. These are established collections based on total populations, not samples.The number of CHIS systems has decreased from over 100 in 2015 to around 70 by mid-2017. As different phases of the digital strategy are implemented across the country, it is anticipated that there may be further temporary local data quality issues associated with the transition. Temporary data quality issues in some London COVER returns during 2017 to 2018 were observed in the quarterly COVER reports as the new Hubs became responsible for generating coverage data. Changes in vaccine coverage within London should therefore be interpreted with caution for the time being.Caution should be exercised when comparing coverage figures over time due to occasional data quality issues reported by some data suppliers. Apparent trends could reflect changes in the quality of data reported as well as real changes in vaccination coverage. While this issue will be more apparent at the local level, it may also impact national figures. Similarly, some caution should be exercised when comparing coverage between different areas where data quality issues have been reported.

Flu vaccine uptake (percent) in at risk individuals aged 6 months to 65 years (excluding pregnant women), who received the flu vaccination between 1st September to the end of February as recorded in the GP record. The February collection has been adopted for our end of season figures from 2017 to 2018. All previous data is the same definitions but until the end of January rather than February to consider data returning from outside the practice and later in practice vaccinations.RationaleInfluenza (also known as Flu) is a highly infectious viral illness spread by droplet infection. The flu vaccination is offered to people who are at greater risk of developing serious complications if they catch the flu. The seasonal influenza programme for England is set out in the Annual Flu Letter. Both the flu letter and the flu plan have the support of the Chief Medical Officer (CMO), Chief Pharmaceutical Officer (CPhO), and Director of Nursing.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine-preventable communicable diseases. Immunisation is one of the most effective healthcare interventions available, and flu vaccines can prevent illness and hospital admissions among these groups of people. Increasing the uptake of the flu vaccine among these high-risk groups should also contribute to easing winter pressure on primary care services and hospital admissions. Coverage is closely related to levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.The UK Health Security Agency (UKHSA) will continue to provide expert advice and monitoring of public health, including immunisation. NHS England now has responsibility for commissioning the flu programme, and GPs continue to play a key role. NHS England teams will ensure that robust plans are in place locally and that high vaccination uptake levels are reached in the clinical risk groups. For more information, see the Green Book chapter 19 on Influenza.The Annual Flu Letter sets out the national vaccine uptake ambitions each year. In 2021 to 2022, the national ambition was to achieve at least 85 percent vaccine uptake in those aged 65 and over. Prior to this, the national vaccine uptake ambition was 75 percent, in line with WHO targets.Definition of numeratorNumerator is the number of vaccinations administered during the influenza season between 1st September and the end of February.Definition of denominatorDenominator is the GP registered population on the date of extraction including patients who have been offered the vaccine but refused it, as the uptake rate is measured against the overall eligible population. For more detailed information please see the user guide, available to view and download from https://www.gov.uk/government/collections/vaccine-uptake#seasonal-flu-vaccine-uptakeCaveatsRead codes are primarily used for data collection purposes to extract vaccine uptake data for patients who fall into one or more of the designated clinical risk groups. The codes identify individuals at risk, and therefore eligible for flu vaccination. However, it is important to note that there may be some individuals with conditions not specified in the recommended risk groups for vaccination, who may be offered influenza vaccine by their GP based on clinical judgement and according to advice contained in the flu letter and Green Book, and thus are likely to fall outside the listed Read codes. Therefore, this data should not be used for GP payment purposes.

Children for whom the local authority is responsible who completed a booster course of diphtheria, tetanus, pertussis, polio (DTaP and IPV) vaccine at any time by their fifth birthday as a percentage of all children whose fifith birthday falls within the time period.RationaleA booster vaccine for diphtheria, tetanus, pertusiss and polio disease has been in the routine childhood immunisation programme since late 2001. It is currently offered at 3 year and 4 months or soon after. Vaccination coverage is the best indicator of the level of protection a population will have against vaccine preventable communicable diseases. Coverage is closely correlated with levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise. Previous evidence shows that highlighting vaccination programmes encourages improvements in uptake levels. May also have relevance for NICE guidance PH21: Reducing differences in the uptake of immunisations (The guidance aims to increase immunisation uptake among those aged under 19 years from groups where uptake is low).Definition of numeratorNumber of children in LA responsible population whose fifth birthday falls within the time period who received a DTaP and IPV booster at any time before their fifth birthday.Definition of denominatorTotal number of children in LA responsible population whose fifth birthday falls within the time period. Coverage figures are supplied for patients registered with GPs based in that LA and for unregistered patients who were resident in that LA. The LA responsible population is therefore different from the estimated resident population figures produced by the Office of National Statistics (ONS) for each LA. For the COVER collection, the LA responsible population is usually derived from the population registers held on CHISs.CaveatsFull GP postcodes are used to aggregate data to ICB. The GP-level coverage data is collected by NHS Digital Strategic Data Collection Service (SDCS) and published by the UK Health Security Agency (UKHSA) COVER team. ICB data is experimental and should be treated with caution as it is not an official statistic.Information on childhood immunisation coverage at ages one, two, and five is collected through the UK COVER collection by UKHSA. These aggregated data are collected from CHISs, computerised systems storing clinical records that support health promotion and prevention activities for children, including immunisation. In England, COVER data are collected for Upper Tier Local Authorities (LAs) using the COVER data collection form. These are established collections based on total populations, not samples.The number of CHIS systems has decreased from over 100 in 2015 to around 70 by mid-2017. As different phases of the digital strategy are implemented across the country, it is anticipated that there may be further temporary local data quality issues associated with the transition. Temporary data quality issues in some London COVER returns during 2017 to 2018 were observed in the quarterly COVER reports as the new Hubs became responsible for generating coverage data. Changes in vaccine coverage within London should therefore be interpreted with caution for the time being.Data are extracted directly from local population registers, and data issues are generally related to underestimation of coverage. There may be some overestimation of denominators due to children who have moved away remaining on the area register, which can lead to underestimates of coverage. In some areas, it is known that a small number of GPs do not submit vaccination data to the local CHIS, also resulting in underestimation of coverage. Using non-standardised data extraction methods could result in overestimated coverage.Caution should be exercised when comparing coverage figures over time due to occasional data quality issues reported by some data suppliers. Apparent trends could reflect changes in the quality of data reported as well as real changes in vaccination coverage. While this issue will be more apparent at the local level, it may also impact national figures. Similarly, some caution should be exercised when comparing coverage between different areas where data quality issues have been reported.

The information in this bulletin, about immunisation statistics in England, comes from: The Health Protection Agency (HPA) Centre for Infections (CfI) for information on childhood immunisation coverage at ages 1, 2 and 5 collected through the Cover of Vaccination Evaluated Rapidly (COVER) data collection for PCTs The NHS Information Centre (The NHS IC) for information about the BCG programme and reinforcing doses on the KC50 return from known providers of immunisation services. The Department of Health for information on persons aged 65 and over immunised against influenza for all PCTs (in conjunction with Health Protection Agency) Subsequent to publishing this report on 30th November 2010 a number of changes were identified as being needed. These are detailed in the Errata note document above. March 2013: Following investigation of KC50 data submitted by some Trusts from 2008-09 through to 2010-11, the HSCIC is recommending that Td/IPV and BCG data reported in tables 6, 7, 13 and 13a of this publication should be treated with some caution. See Errata note above for more information. Please note: Issues with some newly implemented Child Health Information Systems (CHISs) over recent years have affected COVER data quality. Although some Primary Care Trusts (PCTs) reported data quality issues in 2009-10, overall fewer issues have been identified. Some caution should, however, be exercised when comparing coverage figures over time as apparent trends could reflect changes in the quality of data reported as well as real changes in vaccination coverage. While this issue will be more apparent at a local level, it will also have an impact on the national figures.

The name and postcode of the GP practice or PCN. The submission date. The number of vaccines administered. The payment made or to be made. Response I can confirm that the NHSBSA holds the information you have requested and a copy of the information is attached. Please read the notes to ensure correct understanding of the data. The NHSBSA calculates payments for Covid-19 vaccinations to Pharmacies and Primary Care Network (PCN) providers in England. Covid19 vaccination data is keyed in via Point of Care (POC) Systems and then transferred to the NHSBSA Manage Your Service (MYS) application. Each month, vaccine providers submit claims to request payment based on the data that has been transferred into MYS. To be paid in a timely fashion, claims must be submitted during a specified declaration submission period. Should claims be submitted outside the submission period, they will be processed in the following period. This means that in some cases there is a difference between the number of vaccines ‘claimed' and the number that have been 'paid'. We do not hold Primary Care Network (PCN) Grouping data that we can confidently join to the GP Practice Organisation Data Service (ODS) Code. Data is provided for the GP Practice ODS Code that represented its whole PCN Grouping for the purpose of claiming fees for Covid-19 vaccines. The names, addresses and postcodes of GP practices is publicly available via the NHS Digital ODS data here https://digital.nhs.uk/services/organisation-data-service/export-data-files/csv-downloads/gp-and-gp-practice-related-data Each provided ODS code can be linked to GP practice address and post code data in the epraccur dataset or using other ODS tools such as ODS portal search or ODS data point. Both the number of 'claimed' and 'paid' vaccinations have been reported in this request. We have included values for the total payment calculated, with an additional column for any ancillary payment calculated after the original payment. Data included in this request is limited to vaccinations carried out by PCNs only. As requested, we have chosen to report by Submission Date. Data included in this request is also limited to vaccinations administered between December 2020 and August 2024. The latest data used is a snapshot of the MYS system data that was taken on Friday 6 September 2024. This is the snapshot of data taken after the August 2024 submission period that was used to calculate payments. This payment data does not include any adjustments made by NHSBSA Provider Assurance as part of post payment verification exercise. Any adjustments are made at account level and may relate to several months of activity. This data does not include data for claim submissions made in February 2021, as these were deleted and resubmitted later to apply the revised fee rates. In this month, there was a clawback of some payments and most of these clawbacks are excluded from this report and with the data reported against the resubmission. But during this period, there were some manual adjustments that may not all be reflected in the itemised records. Payment data includes payments made and any scheduled for payment in the future. Payments comprise of an Item of Service fee and a supplementary fee where applicable. Payments do not relate to the value of the drugs dispensed. For doses administered between September 2021 and January 2022, there was a range of late notice fee rate changes. Over this time, the pre-established rates were claimed and paid as normal. Top up payments were made later in February, March and May 2022 to bring the total paid to that implied by the late notice fee rate changes. These top ups were calculated separately, but they did not require a new submission - so these have been reported against the original submission date for the dose that would have led to the standard payment. These top up payments are shown as 'Ancillary Payment Amount GBP'. The total used for the payment calculation may not match the totals shown in 'live' POC systems or MYS that continue to receive updates after the snapshot used to calculate payments was taken. Vaccination records are limited to those which have been associated with a declaration submission. This may include late submission declarations received after the deadline for declarations such records are not processed until the next month. This report may include claims for tokens that have exceeded the applicable grace period (currently 3 months) at the time they were processed; such doses will not be included in the payment. This report does not include data for doses claimed after the 15-day period between date supplied and date recorded in the point of care system. Please note that some vaccinations attract a supplementary fee, so it is not possible to determine the number of vaccinations by dividing the total paid by the basic Item of Service (IoS) fee.

The information in this bulletin, about immunisation statistics in England, comes from: The Health Protection Agency (HPA) and Health Protection Services (HPS) - for information on childhood immunisation coverage at ages 1, 2 and 5. It is collected through the Cover of Vaccination Evaluated Rapidly (COVER) data collection for PCTs. The NHS Information Centre (The NHS IC) - for information about the BCG programme and reinforcing doses of diphtheria, tetanus and polio on the KC50 return from known providers of immunisation services. The Department of Health - for information on persons aged 65 and over immunised against seasonal flu for all PCTs (in conjunction with Health Protection Agency). Subsequent to publishing this report on 28 September 2011, a number of changes were identified as being needed. For full details please see the Errata note document above. March 2013:Following investigation of KC50 data submitted by some Trusts from 2008-09 through to 2010-11, the HSCIC is recommending that Td/IPV and BCG data reported in tables 6, 7, 13 and 13a of this publication should be treated with some caution. See Errata note above for more information.

Routine childhood vaccination is important to protect our children against ill health. Vaccines prevent up to 3 million deaths worldwide every year. After clean water, vaccination is the most effective public health intervention in the world for saving lives and promoting good health.Since vaccines were introduced in the UK, diseases like smallpox, polio and tetanus that used to kill or disable millions of people are either gone or seen very rarely. Other diseases like measles and diphtheria have been reduced by up to 99.9% since their vaccines were introduced. Vaccination is not compulsory, however, if people stop having vaccines, it's possible for infectious diseases to quickly spread again. The overall aim of the UK’s routine childhood immunisation schedule is to provide protection against the following vaccine-preventable infections:

These data describe pneumococcal polysaccharide vaccine (PPV) uptake for the survey year, for those aged 65 years and over.RationaleVaccination coverage is the best indicator of the level of protection a population will have against vaccine preventable communicable diseases. Coverage is closely related to levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise. Pneumococcal disease is a significant cause of morbidity and mortality. Certain groups are at risk for severe pneumococcal disease, these include young children, the elderly and people who are in clinical risk groups2. Pneumococcal infections can be non invasive such as bronchitis, otitis media or invasive such as septicaemia, pneumonia, meningitis. Cases of invasive pneumococcal infection usually peak in the winter during December and January. The pneumococcal polysaccharide vaccine (PPV) protects against 23 types of Streptococcus pneumoniae bacterium. It is thought that the PPV is around 50 percent to 70 percent effective at preventing more serious types of invasive pneumococcal infection2.Since 1992 the 23 valent PPV has been recommended for people in the clinical risk groups and since 2003, the PPV vaccination programme has expanded to include immunisation to all those aged 65 years and over in England1This indicator was judged to be a valid and an important measure of public health and was therefore included in the public health outcomes framework. Inclusion of these indicators will encourage the continued prioritisation and evaluation and the effectiveness of the PPV vaccination programme and give an indication of uptake at an upper tier Local Authority level. The vaccination surveys measure the proportion of eligible people that have received PPV at any time and the proportion that received PPV during the previous year, providing an opportunity to assess the delivery of the immunisation programme11 Pneumococcal Polysaccharide Vaccine (PPV) coverage report, England, April 2013 to March 2014 [online]. 2015 [cited 2015 Mar]. Available from URL: https://www.gov.uk/government/publications/pneumococcal-polysaccharide-vaccine-ppv-vaccine-coverage-estimates 2 Pneumococcal infections, NHS Choices [online]. 2013 [cited 2013 Dec]. Available from URL: http://www.nhs.uk/conditions/vaccinations/pages/pneumococcal-vaccination.aspxDefinition of numeratorUKHSA provided UTLA level data. Clinical commissioning group (CCG) data is available from https://www.gov.uk/government/collections/vaccine-uptake#ppv-vaccine-uptakeDefinition of denominatorNumber of adults aged 65 years and over. Data from 2013 to 2014 are now available at source at a local authority level. Data prior to 2013 to 2014 were collected at a PCT level and converted to LA level for inclusion in PHOF using the criteria as defined below:Denominators for local authorities are estimated from denominators for PCTs. Denominators for PCTs include all people registered with practices accountable to the PCT, and no data are available to provide resident-based figures. Denominators for local authorities are estimated as follows: (For local authorities that have exactly the same boundary as a PCT, the PCT figure is used as it is the only estimate available for the residents of the PCT and local authority. For local authorities whose boundary is contained wholly within a single PCT, but is not equal to the whole PCT, the LA denominator is estimated as a proportion of the PCT figure, with the exceptions of Isles of Scilly, City of London, Rutland, Cornwall, Hackney and Leicestershire (see below). For local authorities whose boundaries include all or part of more than one PCT, the local authority denominator is estimated by aggregating the appropriate proportions of the denominators for the PCTs whose boundaries include part of the local authority. The appropriate proportions in cases ii and iii are defined according to the resident population (in the appropriate age group) in the calendar year overlapping most of the period of the indicator value (or the most recent available): resident population by Lower Layer Super Output Area were extracted and used to calculate the population resident in every LA PCT overlapping block.To calculate the denominator, each LA PCT overlap is calculated as a proportion of the PCT resident population, and then multiplied by the denominator for the PCT. A LA may overlap several PCTs: the appropriate portions of all the PCTs’ denominators are aggregated to give the denominator estimate for the LA. Expressed as an equation the denominator is calculated as follows: DenominatorLA = ∑ (DenominatorPCT × n/N) summed over all PCTs overlapping the LA where: DenominatorLA = Estimated denominator in the LA n = Population resident in the LA-PCT overlapping block N = Population resident in the PCT DenominatorPCT = Denominator in the PCT For Isles of Scilly, City of London and Rutland, no indicator data are presented (prior to 2013 to 2014), as the local authority makes up a very small proportion of the PCT, and estimates for the LAs based on the PCT figures are unlikely to be representative as they are swamped by the much larger local authority within the same PCT. The estimates for Cornwall, Hackney and Leicestershire local authorities are combined data for Cornwall and Isles of Scilly, City of London and Hackney, and Leicestershire and Rutland respectively in order to ensure that all valid PCT data are included in the England total.Denominators for Cornwall and Isles of Scilly, City of London and Hackney, and Leicestershire and Rutland are not combined for the 2019 to 2020 annual local authority level data."CaveatsThe pneumococcal vaccine uptake collection is a snapshot of GP patients vaccinated currently registered at the time of data extraction. The proportion of GP practices who provided data for the surveys are available from the uptake reports. Data will exclude patients who have received the vaccine but have subsequently died, patients who have since moved, or patients that are vaccinated but have not had their electronic patient record updated by the time of data extraction. Data for local authorities prior to 2013 to 2014 have been estimated from registered PCT level indicators. While the majority of patients registered with practices accountable to a PCT tend to be resident within that PCT, there are, in some PCTs, significant differences between their resident and registered populations. Therefore the estimates for LAs may not always accurately reflect the resident population of the local authority (LA). Please note that the PCT response rate should be checked for data completeness as this will have a knock on effect to the LA values.

Objective: To evaluate the effectiveness and cost of the pan-London pharmacy initiative, a programme that allows administration of seasonal influenza vaccination to eligible patients at pharmacies. Design: We analysed 2013–15 data on vaccination uptake in pharmacies via the Sonar reporting system, and the total vaccination uptake via 2011–15 ImmForm GP reporting system data. We conducted an online survey of London pharmacists who participate in the programme to assess time use data, vaccine choice, investment costs, and opinions about the programme. We conducted an online survey of London GPs to assess vaccine choice of vaccine and opinions about the pharmacy vaccine delivery programme. Setting: All London boroughs. Participants: London-based GPs, and pharmacies that currently offer seasonal flu vaccination. Interventions: Not applicable. Main outcome measures: Comparison of annual vaccine uptake in London across risk groups from years before pharmacy vaccination introduction to after pharmacy vaccination introduction. Completeness of vaccine uptake reporting data. Cost to the NHS of flu vaccine delivery at pharmacies with that at GPs. Cost to pharmacists of flu delivery. Opinions of pharmacists and GPs regarding the flu vaccine pharmacy initiative. Results: No significant change in the uptake of seasonal vaccination in any of the risk groups as a result of the pharmacy initiative. While on average a pharmacy-administered flu vaccine dose costs the NHS up to £2.35 less than a dose administered at a GP, a comparison of the two recording systems suggests there is substantial loss of data. Conclusions: Flu vaccine delivery through pharmacies shows potential for improving convenience for vaccine recipients. However, there is no evidence that vaccination uptake increases and the use of two separate recording systems leads to time consuming data entry and missing vaccine record data.

All children at age 12 months who have received the complete course (3 doses) of hepatitis B vaccine within each reporting area as a percentage of all the eligible population as defined in the hepatitis B chapter of the immunisation against infectious diseases "Green Book" (have maternal Hep B positive status).RationaleInfants born to hepatitis B virus (HBV) infected mothers are at high risk of acquiring HBV infection themselves. Babies born to infected mothers are given a dose of the hepatitis B vaccine after they are born. This is followed by another two doses (with a month in between each) and a booster dose 12 months later. Around 20% of people with chronic hepatitis B will go on to develop scarring of the liver (cirrhosis), which can take 20 years to develop, and around 1 in 10 people with cirrhosis will develop liver cancer.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine preventable communicable diseases. Coverage is closely correlated with levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.Since April 2000 it has been recommended that all pregnant women in England and Wales should be offered testing for hepatitis B through screening for HBsAg, and that all babies of HBsAg seropositive women should be immunised (HSC 1998 127). A dose of paediatric hepatitis B vaccine is recommended for all infants born to an HBV infected mother as soon as possible after birth, then at 1 and 2, and 12 months of age ( https://www.gov.uk/government/collections/hepatitis-b-guidance-data-and-analysis ). Previous evidence shows that highlighting vaccination programmes encourages improvements in uptake levels may also have relevance for NICE guidance PH21: Reducing differences in the uptake of immunisations (The guidance aims to increase immunisation uptake among those aged under 19 years from groups where uptake is low).Definition of numeratorNumber of children at age 12 months who have received the complete course (3 doses) of hepatitis B vaccine. Numerator counts for local authorities include all people registered with practices in the local authority, and no data are available to provide resident based figures.Definition of denominatorEligible population as defined in the hepatitis B chapter of the immunisation against infectious diseases "Green Book" (have maternal Hep B positive status).Denominators for local authorities include all people registered with practices in the local authority, and no data are available to provide resident based figures.CaveatsThese statistics have been published as ‘experimental statistics’ in the NHS Digital “NHS Immunisation Statistics, England” report. There are a number of issues with the hepatitis B dataset which have either impacted on data quality or have raised potential concerns around the quality of the data. Selective neonatal hepatitis B coverage data are reported by local authority (LA) responsible population for the first time in the 2015 to 2016 publication. Many LAs could not supply complete data on infants born to hepatitis B positive mothers and for a number of other LAs there were data quality issues. It has therefore not been possible to estimate figures for those LAs or describe the quality/completeness of LA data with any accuracy. (see Quality Statement for 2015 to 2016 for more information). Office of Health Improvement and Disparities has also published data for LAs that are co terminus with former PCTs but provided data by PCT rather than LA. These data were not published or validated by NHS Digital.